Healwell AI's Analyst Fan Club Grows Louder, but the Numbers Tell a More Complicated Story

Healwell AI posts Q2 net profit but adjusted EBITDA falls; analysts remain bullish on subscription shift and cash flow improvement.

The gap between Wall Street's enthusiasm and the underlying financials at Healwell AI has rarely been wider. On Tuesday, Maxim Group lifted the Canadian health-tech firm to "Strong Buy," just weeks after Canaccord Genuity upgraded its own rating on July 28. The consensus now sits at Strong Buy, built on two Strong Buy ratings and one Buy — yet the company's own second-quarter results, released days before those upgrades, paint a picture of a business still very much in transition.

A Profit That Deserves a Second Look

Healwell AI swung to a net profit of 6.4 million Canadian dollars from continuing operations in Q2 2026, a dramatic reversal from the 4.1 million dollar loss recorded in the same period a year earlier. But that headline number obscures a more sobering operational reality. Adjusted EBITDA actually contracted, falling from 2.3 million to 1.1 million dollars year-over-year, squeezed by the divestment of Mutuo at the end of 2025 and a weaker margin mix in the life sciences segment.

Revenue held essentially flat at 33.0 million dollars versus 33.2 million in the prior-year quarter. The composition, however, shifted meaningfully: recurring subscription revenue from the enterprise business offset the disappearance of project-based consulting work. Management's pivot toward a subscription model is strategically defensible — recurring revenue typically commands richer valuations than one-off projects — but the cost of that transformation is showing up directly in the margin line.

The Cash Flow Bright Spot

Amid the mixed operating metrics, one figure stands out as genuinely encouraging. Operating cash flow for the first half of 2026 came in at 4.5 million dollars, a 14.3 million dollar improvement over the 9.9 million dollar cash burn recorded in the same stretch of 2025. That swing suggests the company is making real progress on its own merits, independent of one-off gains or asset sales.

Those gains, though, are worth examining. During the Q2 earnings call, management disclosed that its indirect stake in SpaceX was valued at roughly 23 million Canadian dollars as of June 30, 2026. The plan is to monetize that position by February 2027 to shore up liquidity. It's a sensible financial maneuver, but it's not the core business — and investors buying the stock for its SpaceX exposure are effectively wagering on a side bet rather than on Healwell's AI strategy.

Guidance Tightens, Targets Hold

The company has trimmed its 2026 growth forecast for the AI and data science segment to the lower end of its previously guided 30 to 50 percent range. Management attributes the slowdown to longer enterprise sales cycles — a pattern echoing across the broader software industry right now, rather than a company-specific problem.

At the same time, Healwell is sticking with its goal of reaching roughly 10 percent adjusted EBITDA margin by year-end, leaning on cross-selling opportunities for AI tools like SMART Search and SMART Summary into Orion Health's existing customer base. Whether that target holds depends heavily on how quickly the weaker revenue mix normalizes.

Analysts Split on the Right Price

The analyst community has responded to the Q2 report with notably divergent views. Scotiabank raised its price target to 2.00 Canadian dollars from 1.50 on July 30 — though that call came before the quarterly numbers landed. Haywood's Gianluca Tucci took a more measured approach after the release, reaffirming his Buy recommendation but cutting his target to 1.75 dollars, citing lower estimates and sector-wide compression of SaaS multiples. Alliance Global Partners, meanwhile, confirmed a Buy with a 1.50 dollar target on the same day.

The average analyst price target now sits at 2.30 Canadian dollars, implying a premium of more than 214 percent over Monday's close in Toronto. That kind of gap between price and target can signal either substantial perceived upside or a valuation fraught with uncertainty — and Healwell's still-negative profit margins give skeptics plenty of ammunition.

Two Markets, Two Moods

Monday's trading in North America told an upbeat story. Shares on the Toronto Stock Exchange (AIDX.TO) jumped 8.96 percent to 0.73 Canadian dollars, pushing the market capitalization to roughly 228.45 million dollars. The US-listed Class A shares (HWAIF) followed suit, closing at 0.53 US dollars, up 10.58 percent on volume of about 73,200 shares, after trading between a high of 0.53 and a low of 0.48.

The German market struck a different tone on Tuesday. The stock slipped 2.34 percent to 0.4390 euros, giving back some of Monday's momentum, though it still holds an 8.40 percent gain over the past seven days. The pullback underscores how far the shares remain from their highs: the 52-week peak of 1.05 euros, set on August 13, 2025, still sits roughly 58 percent above the current price, and the stock remains down more than 17 percent on a one-year basis.

The Canadian listing's 52-week range tells a similar story — a high of 1.64 dollars and a low of 0.58 dollars. Healwell AI's recent price action, swinging between sharp gains in North America and a pullback in Europe within a matter of days, reflects a stock driven far more by expectations of future growth than by earnings already on the books. The upgrades from Maxim and Canaccord suggest the Street is increasingly willing to take that bet — but the flat revenue, shrinking EBITDA, and cautious guidance all serve as reminders of the operational work still ahead.